Computer tools in the discovery of HIV-1 integrase inhibitors

Future Medicinal Chemistry

Volumn 2, Issue 7, 2010, Pages 1123-1140

  Liao, Chenzhong ^a   Nicklaus, Marc C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 2 MERCAPTOBENZENESULFONAMIDE DERIVATIVE; 2,6 BISBENZYLIDENECYLOHEXANE 1 ONE DERIVATIVE; 4,5 DIHYDROXYPYRIMIDINE CARBOXAMIDE; BENZOIC HYDRAZIDE DERIVATIVE; BETA KETOAMIDE DERIVATIVE; BMS 707035; CATECHOL DERIVATIVE; CINNAMOYL DERIVATIVE; COUMARIN DERIVATIVE; DIKETOBUTANOIC ACID DERIVATIVE; DIKETOHEXENOIC ACID DERIVATIVE; DIOXEPINONE DERIVATIVE; ELVITEGRAVIR; FLAVONE DERIVATIVE; GS 9160; GS 9224; GSK 364735; INTEGRASE INHIBITOR; ISOQUINOLINE SULFONAMIDE DERIVATIVE; LICHEN ACID DERIVATIVE; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; PHTHALIMIDE DERIVATIVE; QUINONE DERIVATIVE; RALTEGRAVIR; SALICYLHYDRAZINE DERIVATIVE; SALICYLPYRAZOLINONE DERIVATIVE; STYRYLQUINOLINE DERIVATIVE; THIAZOLOTHIAZEPINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMPUTER AIDED DESIGN; DENSITY FUNCTIONAL THEORY; DRUG DESIGN; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-HIV AGENTS; DRUG DESIGN; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77954682878     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.193     Document Type: Review

References (121)

1. Anthony NJ. HIV-1 integrase: a target for new AIDS chemotherapeutics. Curr. Top. Med. Chem. 4(9), 979-990 (2004).
2. Bushman FD, Fujiwara T, Craigie R. Retroviral DNA integration directed by HIV integration protein in vitro. Science 249(4976), 1555-1558 (1990).
3. Asante-Appiah E, Skalka AM. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv. Virus. Res. 52, 351-369 (1999).
4. Grobler JA, Stillmock K, Hu B et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl Acad. Sci. USA 99(10), 6661-6666 (2002).
5. LaFemina RL, Schneider CL, Robbins HL et al. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J. Virol. 66(12), 7414-7419 (1992).
6. Egbertson MS. HIV integrase inhabitors: from diketoacids to heterocyclic templates: a history of HIV integrase medicinal chemistry at Merck West Point and Merck Rome (IRBM). Curr. Top. Med. Chem. 7(13), 1251-1272 (2007).
7. Pace P, Rowley M. Integrase inhibitors for the treatment of HIV infection. Curr. Opin. Drug Discov. Devel. 11(4), 471-479 (2008).
8. Marchand C, Maddali K, Metifiot M, Pommier Y. HIV-1 IN inhibitors: 2010 update and perspectives. Curr. Top. Med. Chem. 9(11), 1016-1037 (2009).
9. Al-Mawsawi LQ, Al-Safi RI, Neamati N. Anti-infectives: clinical progress of HIV-1 integrase inhibitors. Expert Opin. Emerg. Drugs 13(2), 213-225 (2008).
10. Anker M, Corales RB. Raltegravir (MK-0518), a novel integrase inhibitor for the treatment of HIV infection. Expert Opin. Investig. Drugs 17(1), 97-103 (2008).
11. Summa V, Petrocchi A, Bonelli F et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 51(18), 5843-5855 (2008).
12. Sato M, Motomura T, Aramaki H et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem. 49(5), 1506-1508 (2006).
13. Shimura K, Kodama E, Sakagami Y et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 82(2), 764-774 (2008).
14. Johns BA, Svolto AC. Advances in two-metal chelation inhibitors of HIV integrase. Expert Opin. Ther. Pat 18(11), 1225-1237 (2008).
15. Liao C, Nicklaus MC. Tautomerism and magnesium chelation of HIV-1 integrase inhibitors: a theoretical study. ChemMedChem. 5, 1053-1066 (2010).
16. Liao C, Marchand C, Burke TR Jr et al. Authentic HIV-1 integrase inhibitors. Future Med. Chem. 2(7), 1107-1122 (2010).
17. Young DC. Computational Drug Design: A Guide for Computational and Medicinal Chemists. John Wiley & Sons, Inc., NY, USA (2009).
18. Skjevik AA, Teigen K, Martinez A. Overview of computational methods employed in early-stage drug discovery. Future Med. Chem. 1(1), 49-63 (2009).
19. Tanrikulu Y, Schneider G. Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening. Nat. Rev. Drug Discov. 7(8), 667-677 (2008).
20. Tuccinardi T. Docking-based virtual screening: recent developments. Comb. Chem. High. Throughput Screen. 12(3), 303-314 (2009).
21. Clark DE. What has computer-aided molecular design ever done for drug discovery? Expert Opin. DrugDiscov. 1(2), 103-110 (2006).
22. Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. Nat. Rev. Drug Discov. 4(8), 649-663 (2005).
23. Potemkin V, Grishina M. Principles for 3D/4D QSAR classification of drugs. Drug Discov. Today 13(21-22), 952-959 (2008).
24. Debnath AK. Quantitative structure-activity relationship (QSAR) paradigm-Hansch era to new millennium. Mini. Rev. Med. Chem. 1(2), 187-195 (2001).
25. Nicklaus MC, Neamati N, Hong H et al. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J. Med. Chem. 40(6), 920-929 (1997). (Pubitemid 27131621)
26. Hong H, Neamati N, Wang S et al. Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J. Med. Chem. 40(6), 930-936 (1997). (Pubitemid 27131622)
27. Neamati N, Hong H, Mazumder A et al. Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. J. Med. Chem. 40(6), 942-951 (1997). (Pubitemid 27131624)
28. Neamati N, Hong H, Sunder S et al. Potent inhibitors of human immunodeficiency virus type 1 integrase: identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors. Mol. Pharmacol. 52(6), 1041-1055 (1997).
29. Hong H, Neamati N, Winslow HE et al. Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Antivir. Chem. Chemother. 9(6), 461-472 (1998).
30. Mustata GI, Brigo A, Briggs JM. HIV-1 integrase pharmacophore model derived from diverse classes of inhibitors. Bioorg. Med. Chem. Lett. 14(6), 1447-1454 (2004).
31. Barreca ML, Rao A, De Luca L et al. Efficient 3D database screening for novel HIV-1 IN inhibitors. J. Chem. Inf. Comput. Sci. 44(4), 1450-1455 (2004).
32. Barreca ML, Ferro S, Rao A et al. Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors. J. Med. Chem. 48(22), 7084-7088 (2005).
33. Dayam R, Sanchez T, Clement O et al. p-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors. J. Med. Chem. 48(1), 111-120 (2005).
34. Dayam R, Sanchez T, Neamati N. Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase. J. Med. Chem. 48(25), 8009-8015 (2005). (Pubitemid 41798431)
35. Deng J, Sanchez T, Al-Mawsawi LQ et al. Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore. Bioorg. Med. Chem. 15(14), 4985-5002 (2007).
36. De Luca L, Barreca ML, Ferro S et al. A refined pharmacophore model for HIV-1 integrase inhibitors: optimization of potency in the 1H-benzylindole series. Bioorg. Med. Chem. Lett. 18(9), 2891-2895 (2008).
37. Dayam R, Al-Mawsawi LQ, Zawahir Z et al. Quinolone 3-carboxylic acid pharmacophore: design of second generation HIV-1 integrase inhibitors. J. Med. Chem. 51(5), 1136-1144 (2008).
38. Milne GW, Nicklaus MC, Driscoll JS et al. National Cancer Institute drug information system 3D database. J. Chem. Inf. Comput. Sci. 34(5), 1219-1224 (1994).
39. Kawasuji T, Yoshinaga T, Sato A et al. A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores. Bioorg. Med. Chem. 14(24), 8430-8445 (2006).
40. Kawasuji T, Fuji M, Yoshinaga T et al. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors. Bioorg. Med. Chem. 14(24), 8420-8429 (2006).
41. Hazuda DJ, Anthony NJ, Gomez RP et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl Acad. Sci. 101(31), 11233-11238 (2004).
42. Jorgensen WL, Tirado-Rives J. Molecular modeling of organic and biomolecular systems using BOSS and MCPRO. J. Comput. Chem. 26(16), 1689-1700 (2005).
43. Carlson HA, Masukawa KM, Rubins K et al. Developing a dynamic pharmacophore model for HIV-1 integrase. J. Med. Chem. 43(11), 2100-2114 (2000).
44. Deng J, Lee KW, Sanchez T et al. Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors. J. Med. Chem. 48(5), 1496-1505 (2005).
45. Deng J, Sanchez T, Neamati N, Briggs JM. Dynamic pharmacophore model optimization: identification of novel HIV-1 integrase inhibitors. J. Med. Chem. 49(5), 1684-1692 (2006).
46. Lins RD, Briggs JM, Straatsma TP et al. Molecular dynamics studies on the HIV-1 integrase catalytic domain. Biophys. J. 76(6), 2999-3011 (1999).
47. Kier LB, Hall LH. An electrotopological-state index for atoms in molecules. Pharm. Res. 7(8), 801-807 (1990).
48. Rogers D, Hopfinger AJ. Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J. Chem. Inf. Comput. Sci. 34(4), 854-866 (2002).
49. Ponce YM. Total and local quadratic indices of the molecular pseudograph's atom adjacency matrix: applications to the prediction of physical properties of organic compounds. Molecules 8(9), 687-726 (2003).
50. Consonni V, Todeschini R, Pavan M. Structure/response correlations and similarity/diversity analysis by GETAWAY descriptors. 1. Theory of the novel 3D molecular descriptors. J. Chem. Inf. Comput. Sci. 42(3), 682-692 (2002). (Pubitemid 35355277)
51. Specht DF. Probabilistic neural networks. Neural Networks 3(1), 109-118 (1990).
52. Cramer RD, Patterson DE, Bunce JD. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110(18), 5959-5967 (2002).
53. Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 37(24), 4130-4146 (1994).
54. Ferguson AM, Heritage T, Jonathon P et al. EVA: a new theoretically based molecular descriptor for use in QSAR/QSPR analysis. J. Comput. AidedMol. Des. 11(2), 143-152 (1997).
55. Polanski J, Walczak B. The comparative molecular surface analysis (COMSA): a novel tool for molecular design. Comput. Chem. 24(5), 615-625 (2000).
56. Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 28(7), 849-857 (1985).
57. Baroni M, Costantino G, Cruciani G et al. Generating optimal linea r PL S estimations (GOLPE): an advanced chemometric tool for handling 3D-QSAR problems. Quant. Struct. Act. Relat. 12(1), 9-20 (1993).
58. Datar PA, Khedkar SA, Malde AK, Coutinho EC. Comparative residue interaction analysis (CoRIA): a 3D-QSAR approach to explore the binding contributions of active site residues with ligands. J. Comput. AidedMol. Des. 20(6), 343-360 (2006).
59. Duca JS, Hopfinger AJ. Estimation of molecular similarity based on 4D-QSAR analysis: formalism and validation. J. Chem. Inf. Comput. Sci. 41(5), 1367-1387 (2001).
60. Raghavan K, Buolamwini JK, Fesen MR et al. Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study. J Med. Chem. 38(6), 890-897 (1995).
61. Buolamwini JK, Raghavan K, Fesen MR et al. Application of the electrotopological state index to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors. Pharm. Res. 13(12), 1892-1895 (1996).
62. Makhija MT, Kulkarni VM. Eigen value analysis of HIV-1 integrase inhibitors. J. Chem. Inf. Comput. Sci. 41(6), 1569-1577 (2001).
63. Buolamwini JK, Assefa H. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. J. Med. Chem. 45(4), 841-852 (2002).
64. Makhija MT, Kulkarni VM. QSAR of HIV-1 integrase inhibitors by genetic function approximation method. Bioorg. Med. Chem. 10(5), 1483-1497 (2002).
65. Makhija MT, Kulkarni VM. Molecular electrostatic potentials as input for the alignment of HIV-1 integrase inhibitors in 3D QSAR. J. Comput. Aided Mol. Des. 15(11), 961-978 (2001).
66. Makhija MT, Kulkarni VM. 3D-QSAR and molecular modeling of HIV-1 integrase inhibitors. J. Comput. Aided Mol. Des. 16(3), 181-200 (2002).
67. Yuan H, Parrill AL. QSAR studies of HIV-1 integrase inhibition. Bioorg. Med. Chem. 10(12), 4169-4183 (2002).
68. Costi R, Santo RD, Artico M et al. 2,6-bis(3,4,5-trihydroxybenzylydene) derivatives of cyclohexanone: novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays. Bioorg. Med. Chem. 12(1), 199-215 (2004).
69. Makhija MT, Kasliwal RT, Kulkarni VM, Neamati N. De novo design and synthesis of HIV-1 integrase inhibitors. Bioorg. Med. Chem. 12(9), 2317-2333 (2004). (Pubitemid 38471716)
70. Kuo CL, Assefa H, Kamath S et al. Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzene-sulfonamides as HIV-1 integrase inhibitors. J. Med. Chem. 47(2), 385-399 (2004).
71. Daeyaert FFD, Vinkers HM, Jonge MRD et al. Ligand-based computation of HIV-1 integrase inhibition strength within a series of p-ketoamide derivatives. internet electron. J. Mol. Des. 3(9), 528-543 (2004).
72. Marrero-Ponce Y. Linear indices of the "molecular pseudograph's atom adjacency matrix": definition, significance-interpretation, and application to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors. J. Chem. Inf. Comput. Sci. 44(6), 2010-2026 (2004).
73. Di Santo R, Costi R, Artico M et al. Design, synthesis and biological evaluation of heteroaryl diketohexenoic and diketobutanoic acids as HIV-1 integrase inhibitors endowed with antiretroviral activity. Farmaco 60(5), 409-417 (2005).
74. Yuan H, Parrill A. Cluster analysis and three-dimensional QSAR studies of HIV-1 integrase inhibitors. J. Mol. Graph. Model. 23(4), 317-328 (2005).
75. Nunthaboot N, Tonmunphean S, Parasuk V et al. Three-dimensional quantitative structure: activity relationship studies on diverse structural classes of HIV-1 integrase inhibitors using CoMFA and CoMSIA. Eur. J. Med. Chem. 41(12), 1359-1372 (2006).
76. Niedbala H, Polanski J, Gieleciak R et al. Comparative molecular surface analysis (CoMSA) for virtual combinatorial library screening of styrylquinoline HIV-1 blocking agents. Comb. Chem. High. Throughput Screen. 9(10), 753-770 (2006).
77. Vilar S, Santana L, Uriarte E. Probabilistic neural network model for the in silico evaluation of anti-HIV activity and mechanism of action. J. Med. Chem. 49(3), 1118-1124 (2006).
78. Saiz-Urra L, Gonzalez MP, Fall Y, Gomez G. Quantitative structure-activity relationship studies of HIV-1 integrase inhibition. 1. GETAWAY descriptors. Eur. J. Med. Chem. 42(1), 64-70 (2007).
79. Leonard JT, Roy K. Exploring molecular shape analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors. Eur. J. Med. Chem. 43(1), 81-92 (2008).
80. Iyer M, Hopfinger AJ. Treating chemical diversity in QSAR analysis: modeling diverse HIV-1 integrase inhibitors using 4D fingerprints. J. Chem. Inf. Model. 47(5), 1945-1960 (2007).
81. Dhaked DK, Verma J, Saran A, Coutinho EC. Exploring the binding of HIV-1 integrase inhibitors by comparative residue interaction analysis (CoRIA). J. Mol. Model. 15(3), 233-245 (2009).
82. Dessalew N. Investigation of the structural requirement for inhibiting HIV integrase: QSAR study. Acta. Pharm. 59(1), 31-43 (2009).
83. de Melo EB, Ferreira MM. Multivariate QSAR study of 4,5- dihydroxypyrimidine carboxamides as HIV-1 integrase inhibitors. Eur. J. Med. Chem. 44(9), 3577-3583 (2009).
84. Nikitin S, Zaitseva N, Demina O et al. A very large diversity space of synthetically accessible compounds for use with drug design programs. J. Comput. Aided Mol. Des. 19(1), 47-63 (2005).
85. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 4(3), 236-248 (2005).
86. Heuer TS, Brown PO. Photo-cross-linking studies suggest a model for the architecture of an active human immunodeficiency virus type 1 integrase-DNA complex. Biochemistry 37(19), 6667-6678 (1998).
87. Dyda F, Hickman AB, Jenkins TM et al. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 266(5193), 1981-1986 (1994).
88. Lodi PJ, Ernst JA, Kuszewski J, Hickman AB et al. Solution structure of the DNA binding domain of HIV-1 integrase. Biochemistry 34(31), 9826-9833 (1995).
89. Bujacz G, Jaskolski M, Alexandratos J et al. High-resolution structure of the catalytic domain of avian sarcoma virus integrase. J. Mol. Biol. 253(2), 333-346 (1995).
90. Chen JC, Krucinski J, Miercke LJ et al. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc. Natl Acad. Sci. USA 97(15), 8233-8238 (2000).
91. Gao K, Butler SL, Bushman F. Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes. EMBOJ. 20(13), 3565-3576 (2001).
92. Wang JY, Ling H, Yang W, Craigie R. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J. 20(24), 7333-7343 (2001).
93. Podtelezhnikov AA, Gao K, Bushman FD, McCammon JA. Modeling HIV-1 integrase complexes based on their hydrodynamic properties. Biopolymers 68(1), 110-120 (2003).
94. Cai M, Zheng R, Caffrey M et al. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat. Struct. Biol. 4(7), 567-577 (1997).
95. Goldgur Y, Dyda F, Hickman AB et al. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc. Natl Acad. Sci. USA 95(16), 9150-9154 (1998).
96. De Luca L, Pedretti A, Vistoli G et al. Analysis of the full-length integrase-DNA complex by a modified approach for DNA docking. Biochem. Biophys. Res. Commun. 310(4), 1083-1088 (2003).
97. De Luca L, Vistoli G, Pedretti A et al. Molecular dynamics studies of the full-length integrase-DNA complex. Biochem. Biophys. Res. Commun. 336(4), 1010-1016 (2005).
98. Goldgur Y, Craigie R, Cohen GH et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl Acad. Sci. USA 96(23), 13040-13043 (1999).
99. Karki RG, Tang Y, Burke TR Jr, Nicklaus MC. Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design. J. Comput. Aided Mol. Des. 18(12), 739-760 (2004).
100. Bujacz G, Alexandratos J, Wlodawer A et al. Binding of different divalent cations to the active site of avian sarcoma virus integrase and their effects on enzymatic activity. J. Biol. Chem. 272(29), 18161-18168 (1997).
101. Wielens J, Crosby IT, Chalmers DK. A three-dimensional model of the human immunodeficiency virus type 1 integration complex. J. Comput. Aided Mol. Des. 19(5), 301-317 (2005).
102. Maignan S, Guilloteau JP, Zhou-Liu Q et al. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J. Mol. Biol. 282(2), 359-368 (1998).
103. Davies DR, Goryshin IY, Reznikoff WS, Rayment I. Three-dimensional structure of the Tn5 synaptic complex transposition intermediate. Science 289(5476), 77-85 (2000).
104. Wang LD, Liu CL, Chen WZ, Wang CX. Constructing HIV-1 integrase tetramer and exploring influences of metal ions on forming integrase-DNA complex. Biochem. Biophys. Res. Commun. 337(1), 313-319 (2005).
105. Chen A, Weber IT, Harrison RW, Leis J. Identification of amino acids in HIV-1 and avian sarcoma virus integrase subsites required for specific recognition of the long terminal repeat Ends. J. Biol. Chem. 281(7), 4173-4182 (2006).
106. Savarino A. In silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology 4, 21 (2007).
107. Chen X, Tsiang M, Yu F et al. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. J. Mol. Biol. 380(3), 504-519 (2008).
108. Ferro S, De Luca L, Barreca ML et al. Docking studies on a new human immunodeficiency virus integrase-Mg-DNA complex: phenyl ring exploration and synthesis of 1H-benzylindole derivatives through fluorine substitutions. J. Med. Chem. 52(2), 569-573 (2009).
109. Barreca ML, Iraci N, De Luca L, Chimirri A. Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors. ChemMedChem. 4(9), 1446-1456 (2009).
110. Aishima J, Gitti RK, Noah JE et al. A Hoogsteen base pair embedded in undistorted B-DNA. Nucleic Acids Res. 30(23), 5244-5252 (2002).
111. Liao C, Nicklaus MC. HIV-1 integrase-DNA models. In: HIV-1 Integrase: Mechanism and Inhibitor Design. John Wiley & Sons, Inc. (2010) (In Press).
112. Ren G, Gao K, Bushman FD, Yeager M. Single-particle image reconstruction of a tetramer of HIV integrase bound to DNA. J. Mol. Biol. 366(1), 286-294 (2007).
113. Liao C, Karki RG, Marchand C, Pommier Y, Nicklaus MC. Virtual screening application of a model of full-length HIV-1 integrase complexed with viral DNA. Bioorg. Med. Chem. Lett. 17(19), 5361-5365 (2007).
114. Di Santo R, Costi R, Roux A et al. Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action. J. Med. Chem. 49(6), 1939-1945 (2006).
115. Barreca ML, Iraci N, De Luca L, Chimirri A. Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors. ChemMedChem. 4(9), 1446-1456 (2009).
116. Hazuda DJ, Felock P, Witmer M et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287(5453), 646-650 (2000).
117. Frisch MJ, Trucks GW, Schlegel HB et al. Gaussian 03, Revision E.01. Gaussian, Inc. Wallingford, CT, USA (2004).
118. Steiniger-White M, Rayment I, Reznikoff WS. Structure/function insights into Tn5 transposition. Curr. Opin. Struct. Biol. 14(1), 50-57 (2004).
119. Flexner C. HIV drug development: the next 25 years. Nat. Rev. Drug Discov. 6(12), 959-966 (2007).
120. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464(7286), 232-236 (2010).
121. Sitzmann M, Filippov IV, Nicklaus MC. Internet resources integrating many small-molecule databases. SAR QSAR Environ. Res. 19(1-2), 1-9 (2008).